Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ying-tao Lin"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
BackgroundTreating persistent, recurrent, or metastatic cervical cancer remains challenging. Although pembrolizumab, combined with chemotherapy and bevacizumab, offers a promising first-line option, its cost-effectiveness within the Chinese healthcar
Externí odkaz:
https://doaj.org/article/c6fe18137b1e4a0481645ec23180d52d
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: This study evaluated the cost-effectiveness of serplulimab plus chemotherapy versus chemotherapy alone in treating advanced/metastatic esophageal squamous cell carcinoma (ESCC) within the Chinese health care system. Methods: A partitioned
Externí odkaz:
https://doaj.org/article/a34b6917356541339729818c5de953da
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
This study aimed to evaluate and compare nivolumab's cost-effectiveness with chemotherapy in patients with advanced esophageal squamous cell carcinoma from the Chinese healthcare system perspective. To this end, the researchers utilized a partitioned
Externí odkaz:
https://doaj.org/article/c80a1e2e0ffa4fa6bda344a1f829379a
Publikováno v:
Cancer Management and Research
Ying-Tao Lin,1 Ying Chen,2 Tian-Xiu Liu,3 Fang Kuang,1 Ping Huang1 1Administration Office of Drug Clinical Trial, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Peopleâs Republic of China; 2Management Office of Scienc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db695202bfd478d8c1d71ed46c9731e7
http://europepmc.org/articles/PMC8572144
http://europepmc.org/articles/PMC8572144